Scilex Holding Co (SCLX)
1.15
+0.04
(+3.60%)
USD |
NASDAQ |
May 22, 16:00
1.145
0.00 (0.00%)
After-Hours: 20:00
Scilex Cash from Financing (TTM): 1.757M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 1.757M |
December 31, 2023 | 23.58M |
September 30, 2023 | 15.70M |
Date | Value |
---|---|
June 30, 2023 | 47.72M |
March 31, 2023 | -8.16M |
December 31, 2022 | 21.17M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-8.16M
Minimum
Mar 2023
47.72M
Maximum
Jun 2023
16.96M
Average
18.44M
Median
Cash from Financing (TTM) Benchmarks
Sorrento Therapeutics Inc | 246.59M |
Adial Pharmaceuticals Inc | 7.347M |
Precision BioSciences Inc | 44.74M |
Humacyte Inc | 67.71M |
Perspective Therapeutics Inc | 167.19M |